# Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

> **NCT00126659** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **PROCEDURE:** therapeutic conventional surgery
- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00126659
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126659, "Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00126659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*